Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation: https://www.ncbi.nlm.nih.gov/pubmed/15728830

Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942876/

Activation of the CB2 receptor system reverses amyloid-induced memory deficiency: https://www.ncbi.nlm.nih.gov/pubmed/22795792

Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease: https://www.ncbi.nlm.nih.gov/pubmed/21350020